Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Published:2019-06-27 Issue:2 Volume:26 Page:263-270
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Fernandes Samuel Raimundo¹,Bernardo Sónia¹,Simões Carolina¹,Gonçalves Ana Rita¹,Valente Ana¹,Baldaia Cilénia¹,Moura Santos Paula¹,Correia Luís Araújo¹,Tato Marinho Rui¹

Affiliation:

1. Gastrenterology and Hepatology Unit, Hospital Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisboa, Portugal

Abstract

In patients with inflammatory bowel disease, proactive therapeutic drug monitoring of infliximab over a 2-year period was associated with higher rates of mucosal healing and lower surgical requirements compared with a conventional cohort treated without therapeutic drug monitoring.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/26/2/263/31717815/izz131.pdf

Reference27 articles.

1. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials;Cholapranee;Aliment Pharmacol Ther.,2017

2. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis;Mao;Aliment Pharmacol Ther.,2017

3. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse;Papamichael;Inflamm Bowel Dis.,2015

4. Are anti-tumor necrosis factor trough levels predictive of mucosal healing in patients with inflammatory bowel disease?: a systematic review and meta-analysis;Barnes;J Clin Gastroenterol.,2016

5. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease;Moore;J Crohns Colitis.,2016

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease;Journal of Pediatric Gastroenterology and Nutrition;2024-07-09

2. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21

3. Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation;Therapeutic Drug Monitoring;2024-05-15

4. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA;BMJ Open;2024-03

5. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis;World Journal of Gastrointestinal Surgery;2024-02-27